Opioid-Induced Constipation (OIC) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Opioid-Induced Constipation (OIC) – Pipeline Review, H1 2017’, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)

The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects

The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Develco Pharma Schweiz AG

Ironwood Pharmaceuticals Inc

Shionogi & Co Ltd

Sucampo Pharmaceuticals Inc

Synergy Pharmaceuticals Inc

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Opioid-Induced Constipation (OIC) - Overview

Opioid-Induced Constipation (OIC) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opioid-Induced Constipation (OIC) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development

Develco Pharma Schweiz AG

Ironwood Pharmaceuticals Inc

Shionogi & Co Ltd

Sucampo Pharmaceuticals Inc

Synergy Pharmaceuticals Inc

Theravance Biopharma Inc

Opioid-Induced Constipation (OIC) - Drug Profiles

(axelopran sulfate + oxycodone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axelopran sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dolcanatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lubiprostone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylnaltrexone bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naldemedine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opioid-Induced Constipation (OIC) - Dormant Projects

Opioid-Induced Constipation (OIC) - Discontinued Products

Opioid-Induced Constipation (OIC) - Product Development Milestones

Featured News & Press Releases

Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of Naldemedine

Sep 07, 2016: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation

Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation

Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation

Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015

Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients

May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation

May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week

Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Canada

Nov 19, 2014: Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Opioid-Induced Constipation (OIC) – Pipeline by Develco Pharma Schweiz AG, H1 2017

Opioid-Induced Constipation (OIC) – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Opioid-Induced Constipation (OIC) – Pipeline by Shionogi & Co Ltd, H1 2017

Opioid-Induced Constipation (OIC) – Pipeline by Sucampo Pharmaceuticals Inc, H1 2017

Opioid-Induced Constipation (OIC) – Pipeline by Synergy Pharmaceuticals Inc, H1 2017

Opioid-Induced Constipation (OIC) – Pipeline by Theravance Biopharma Inc, H1 2017

Opioid-Induced Constipation (OIC) – Dormant Projects, H1 2017

Opioid-Induced Constipation (OIC) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports